Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP: CYDY )

0.1402 -0.0058 (-3.97%)
Streaming Delayed Price Updated: 12:14 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 Next >
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
From CytoDyn Inc.
Via Business Wire
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
From CytoDyn Inc.
Via Business Wire
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
From CytoDyn Inc.
Via Business Wire
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
From CytoDyn Inc.
Via Business Wire
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
From CytoDyn Inc.
Via Business Wire
CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
From CytoDyn Inc.
Via Business Wire
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
From CytoDyn Inc.
Via Business Wire
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
From CytoDyn Inc.
Via Business Wire
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
From CytoDyn Inc.
Via Business Wire
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
From CytoDyn Inc.
Via Business Wire
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
From CytoDyn Inc.
Via Business Wire
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
From CytoDyn Inc.
Via Business Wire
CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
From CytoDyn Inc.
Via Business Wire
Group of CytoDyn Stockholders Comments on Delaware Court Decision
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
From CytoDyn Inc.
Via Business Wire
These OTC Markets Securities had the Most Trading Activity in September
Photo by Annie Spratt on Unsplash As the 3rd quarter came to a close in September, the OTC Markets saw a slight decrease in total trading volume even as companies reported... 
Via Benzinga
CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”
From CytoDyn Inc.
Via Business Wire
Group of CytoDyn Stockholders Releases White Paper Regarding Company’s Extremely Unfavorable Borrowing Practices
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A
From CytoDyn Inc.
Via Business Wire
Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
From CytoDyn Inc.
Via Business Wire
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
From CytoDyn Inc.
Via Business Wire
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
Via FinancialNewsMedia
Exposures COVID-19
Group of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought by Company
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group
From CytoDyn Inc.
Via Business Wire
Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
Via FinancialNewsMedia
Exposures COVID-19
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.